

**BLISS GVS PHARMA LIMITED**  
Regd Office.102, Hyde Park, Sakivihar Road,  
Andheri (East), Mumbai - 400 072

**STATEMENT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS  
FOR THE QUARTER AND YEAR ENDED 31.03.2016**

PART - I

(Rs. In Lacs)

SR. NO.	PARTICULARS	STANDALONE					CONSOLIDATED	
		QUARTER ENDED			YEAR ENDED		YEAR ENDED	
		31.03.2016 (AUDITED)	31.12.2015 (UNAUDITED)	31.03.2015 (UNAUDITED)	31.03.2016 (AUDITED)	31.03.2015 (AUDITED)	31.03.2016 (AUDITED)	31.03.2015 (AUDITED)
1	<b>INCOME FROM OPERATIONS</b>							
	(a) NET SALES ( NET OF EXCISE DUTY)	6092.27	8625.60	6796.32	31969.24	30945.89	53671.30	40307.34
	(b) OTHER OPERATING INCOME	468.01	61.08	68.51	669.11	356.28	1018.11	406.10
	<b>TOTAL INCOME FROM OPERATIONS( NET)</b>	<b>6560.28</b>	<b>8686.68</b>	<b>6864.83</b>	<b>32638.35</b>	<b>31302.17</b>	<b>54689.41</b>	<b>40713.44</b>
2	<b>EXPENSES</b>							
	a) CONSUMPTION OF RAW MATERIALS	3143.84	3147.08	2,946.33	13,490.28	13,784.13	25589.07	16456.36
	b) PURCHASE OF TRADED GOODS	0.00	0.00	0.00	36.37	90.32	508.76	933.42
	c) CHANGES IN INVENTORIES OF FINISHED GOODS ,WORK IN PROGRESS, STOCK IN	124.02	-80.18	113.10	-132.09	248.27	-421.30	364.87
	d) EMPLOYEE BENEFIT EXPENSES	562.60	579.64	469.38	2188.89	1736.08	3373.65	2942.90
	e) DEPRECIATION / AMORTISATION	143.92	148.44	145.07	585.24	507.83	1326.00	1129.62
	f) OTHER EXPENDITURE	1164.32	2469.76	2040.08	7445.08	6823.95	10108.90	9671.97
	<b>TOTAL EXPENSES</b>	<b>5138.70</b>	<b>6264.74</b>	<b>5713.96</b>	<b>23613.77</b>	<b>23190.58</b>	<b>40485.08</b>	<b>31499.14</b>
3	<b>PROFIT FROM OPERATIONS BEFORE OTHER INCOME &amp; FINANCE COST &amp; EXCEPTIONAL ITEMS ( 1-2)</b>	<b>1421.58</b>	<b>2421.94</b>	<b>1150.87</b>	<b>9024.58</b>	<b>8111.59</b>	<b>14204.33</b>	<b>9214.30</b>
4	OTHER INCOME	267.33	573.21	213.17	2307.57	2135.03	2435.00	2028.86
5	<b>PROFIT FROM ORDINARY ACTIVITIES BEFORE FINANCE COST ( 3+4)</b>	<b>1688.91</b>	<b>2995.15</b>	<b>1364.04</b>	<b>11332.15</b>	<b>10246.63</b>	<b>16639.33</b>	<b>11243.16</b>
6	FINANCE COST	305.13	298.43	296.42	1310.98	1121.18	1819.86	1641.24
7	<b>PROFIT FROM ORDINARY ACTIVITIES AFTER FINANCE COST BUT BEFORE EXCEPTIONAL ITEMS (5-6)</b>	<b>1383.78</b>	<b>2696.72</b>	<b>1067.62</b>	<b>10021.17</b>	<b>9125.45</b>	<b>14819.47</b>	<b>9601.92</b>
8	EXCEPTIONAL ITEMS		-				-	
9	<b>PROFIT FROM ORDINARY ACTIVITIES BEFORE TAX ( 7 - 8)</b>	<b>1383.78</b>	<b>2696.72</b>	<b>1067.62</b>	<b>10021.17</b>	<b>9125.45</b>	<b>14819.47</b>	<b>9601.92</b>
10	TAX EXPENSE (INCLUDING DEFERRED TAX)	915.71	559.80	421.51	3459.70	3123.90	4804.91	3462.58
11	<b>NET PROFIT AFTER TAX FOR THE PERIOD ( 9 - 10)</b>	<b>468.07</b>	<b>2136.92</b>	<b>646.11</b>	<b>6561.47</b>	<b>6001.55</b>	<b>10014.56</b>	<b>6139.34</b>
12	MINORITY INTEREST						-1766.30	-148.37
13	<b>NET PROFIT AFTER TAX &amp; MINORITY INTEREST (11-12)</b>	<b>468.07</b>	<b>2136.92</b>	<b>646.11</b>	<b>6561.47</b>	<b>6001.55</b>	<b>8248.26</b>	<b>5990.97</b>
14	PAID - UP EQUITY CAPITAL	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
15	RESERVES EXCLUDING REVALUATION RESERVE (AS PER BALANCE SHEET )				42175.96	35787.14	40230.77	32676.83
16	<b>BASIC AND DILUTED EPS (NOT ANNUALISED)</b>	<b>0.45</b>	<b>2.07</b>	<b>0.63</b>	<b>6.36</b>	<b>5.82</b>	<b>8.00</b>	<b>5.81</b>

## STATEMENT OF ASSETS AND LIABILITIES AS AT 31st March, 2016

(Rs in Lacs)

	Particulars	STANDALONE		CONSOLIDATED	
		Mar-16	Mar-15	Mar-16	Mar-15
<b>I.</b>	<b>EQUITY AND LIABILITIES</b>				
<b>1</b>	<b>SHAREHOLDERS' FUNDS :</b>				
	(i) Share Capital	1,031.47	1,031.47	1,031.47	1,031.47
	(ii) Reserves and Surplus	42,175.96	35,787.14	40,230.77	32,676.83
	<b>Sub-total - Shareholders' funds</b>	<b>43,207.43</b>	<b>36,818.61</b>	<b>41,262.24</b>	<b>33,708.30</b>
<b>2</b>	<b>Minority Interest</b>			<b>3,309.57</b>	<b>1,489.18</b>
<b>3</b>	<b>Non- Current liabilities</b>				
	(i) Long term Borrowings	1,184.07	3,020.95	3,824.27	5,725.81
	(ii) Deferred tax liabilities (Net)	827.58	715.30	948.86	885.94
	(iii) Long term provisions	166.84	139.85	181.43	139.85
	<b>Sub-total - Non-current liabilities</b>	<b>2,178.49</b>	<b>3,876.10</b>	<b>4,954.56</b>	<b>6,751.60</b>
<b>4</b>	<b>Current liabilities</b>				
	(i) Short term Borrowings	4,994.61	2,837.62	6,212.38	6,104.21
	(ii) Trade payables	3,506.15	5,046.72	10,848.57	8,033.39
	(iii) Other current liabilities	2,909.99	3,913.46	5,275.63	7,030.05
	(iv) Short term provisions	1,671.81	3,007.62	4,315.23	3,100.09
	<b>Sub-total -current liabilities</b>	<b>13,082.56</b>	<b>14,805.42</b>	<b>26,651.81</b>	<b>24,267.74</b>
	<b>Total.....</b>	<b>58,468.48</b>	<b>55,500.13</b>	<b>76,178.18</b>	<b>66,216.82</b>
<b>II.</b>	<b>ASSETS</b>				
<b>1</b>	<b>Non-current assets</b>				
	(a) Fixed Assets	8,107.45	8,150.39	19,059.22	16,062.00
	(b) Goodwill on Consolidation	-	-	4,375.64	7,376.00
	(c) Non-current Investments	2,059.37	1,922.63	11.02	1.01
	(d) Long term loans and advances	11,044.68	10,135.08	5,677.48	1,026.79
	(e) Other non current assets	-	43.26	-	43.26
	<b>Sub-total - Non-current assets</b>	<b>21,211.50</b>	<b>20,251.36</b>	<b>29,123.36</b>	<b>24,509.06</b>
<b>2</b>	<b>Current assets</b>				
	(a) Inventories	2,194.92	2,251.83	3,867.30	3,370.00
	(b) Trade receivables	25,057.83	21,061.21	30,093.29	24,746.94
	(c) Cash and Bank balances	5,689.76	4,736.77	7,817.66	5,728.93
	(d) Short term loans and advances	3,215.96	6,133.62	5,041.92	7,470.88
	(e) Other current assets	1,098.51	1,065.34	234.65	391.01
	<b>Sub-total - Current assets</b>	<b>37,256.98</b>	<b>35,248.77</b>	<b>47,054.82</b>	<b>41,707.76</b>
	<b>Total.....</b>	<b>58,468.48</b>	<b>55,500.13</b>	<b>76,178.18</b>	<b>66,216.82</b>

**NOTES:-**

- 1.THE ABOVE AUDITED FINANCIAL RESULTS WERE REVIEWED BY THE AUDIT COMMITTEE & WERE THERE AFTER APPROVED BY THE BOARD AT ITS MEETING HELD ON MAY 24, 2016
- 2.THE FIGURES FOR THE QUARTER ENDED MARCH 31, 2016 & 2015 ARE THE BALANCING FIGURES BETWEEN THE AUDITED FIGURES IN RESPECT OF THE FULL FINANCIAL YEAR AND THE YEAR TO DATE PUBLISHED RESULTS FOR THE NINE MONTHS ENDED DECEMBER 31, 2015 & 2014
- 3.THE CONSOLIDATED RESULTS INCLUDES THE AUDITED FINANCIAL RESULTS OF PARENT COMPANY, THE SUBSIDIARIES NAMEDLY BLISS GVS INTERNATIONAL PTE LTD, BLISS INDASI LIFE SCIENCES PVT LTD, BLISS GVS CLINIC HEALTHCARE PTE LTD, KREMOINT PHARMA PVT. LTD., LIFEON LABS PVT LTD, ASTERISK LIFESCIENCES LTD AND SHREE SALES PACK PVT LTD
4. THE TAX EXPENSE FOR THE YEAR ENDED MARCH 31,2016 IS NET OF A REFUND OF RS. 217.33 LACS PERTAINING TO PRIOR YEARS, IN RESPECT OF WHICH A FAVOURABLE ORDER WAS RECEIVED BY THE COMPANY DURING THE QUARTER.
- 5.THE COMPANY OPERATES PRIMARILY IN THE PHARMACEUTICAL BUSINESS AND HENCE HAS ONLY ONE REPORTABLE SEGMENT.  
GEOGRAPHICAL SEGMENT DISCLOSURE:-
  - I) REVENUES WITHIN AND OUTSIDE INDIA FOR THE QUARTER ENDED MARCH 31, 2016 - RS. 375.83 LACS AND RS. 5716.44 LACS
  - II) REVENUES WITHIN AND OUTSIDE INDIA FOR THE YEAR ENDED MARCH 31, 2016- RS. 2045.73 LACS AND RS. 29923.51 LACS RESPECTIVELY
6. THE BOARD HAS RECOMMENDED A DIVIDEND OF 50% i.e Rs. 0.50 PER EQUITY SHARE FOR THE YEAR ENDED 31ST MARCH 2016, WHICH IS SUBJECT TO SHAREHOLDERS' APPROVAL AT THE END OF THE ENSUING ANNUAL GENERAL MEETING.
- 7.FIGURES FOR THE PREVIOUS PERIODS HAVE BEEN REGROUPED/REARRANGED WHEREVER NECESSARY.

PLACE : MUMBAI  
DATE : 24th May 2016

FOR BLISS GVS PHARMA LTD  
SD/-  
S.N. KAMATH  
MANAGING DIRECTOR